DexCom Inc (DXCM)vs908 Devices Inc (MASS)
DXCM
DexCom Inc
$83.03
-1.75%
HEALTHCARE · Cap: $31.90B
MASS
908 Devices Inc
$9.52
+1.82%
HEALTHCARE · Cap: $414.99M
Smart Verdict
WallStSmart Research — data-driven comparison
DexCom Inc generates 8068% more annual revenue ($4.97B vs $60.84M). DXCM leads profitability with a 20.1% profit margin vs -57.0%. DXCM earns a higher WallStSmart Score of 74/100 (B).
DXCM
Strong Buy74
out of 100
Grade: B
MASS
Avoid31
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for DXCM.
Margin of Safety
+47.5%
Fair Value
$12.58
Current Price
$9.52
$3.06 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 38 in profit
Keeps 20 of every $100 in revenue as profit
Strong operational efficiency at 24.3%
Earnings expanding 43.6% YoY
Conservative balance sheet, low leverage
Reasonable price relative to book value
Revenue surging 23.3% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
Trading at 11.9x book value
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -27.2% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : DXCM
The strongest argument for DXCM centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 20.1% and operating margin at 24.3%. Revenue growth of 13.1% demonstrates continued momentum.
Bull Case : MASS
The strongest argument for MASS centers on Debt/Equity, Price/Book, Revenue Growth. Revenue growth of 23.3% demonstrates continued momentum.
Bear Case : DXCM
The primary concerns for DXCM are P/E Ratio, Price/Book.
Bear Case : MASS
The primary concerns for MASS are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
DXCM profiles as a mature stock while MASS is a growth play — different risk/reward profiles.
DXCM carries more volatility with a beta of 1.42 — expect wider price swings.
MASS is growing revenue faster at 23.3% — sustainability is the question.
DXCM generates stronger free cash flow (185M), providing more financial flexibility.
Bottom Line
DXCM scores higher overall (74/100 vs 31/100), backed by strong 20.1% margins and 13.1% revenue growth. MASS offers better value entry with a 47.5% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
DexCom Inc
HEALTHCARE · MEDICAL DEVICES · USA
DexCom, Inc. is a company that develops, manufactures, and distributes continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with headquarters in San Diego, California, and has a manufacturing facility in Mesa, Arizona.
908 Devices Inc
HEALTHCARE · MEDICAL DEVICES · USA
908 Devices Inc. develops and sells measuring devices for chemical and biochemical analysis in North America, Europe, the Middle East, Africa, and Asia Pacific. The company is headquartered in Boston, Massachusetts.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?